Loading patent…
AssigneeDaiichi Pharmaceutical Co., Ltd.
InventorsMasahiko Kinosaki, Kyoji Yamaguchi, Fumie Kobayashi, Masaaki Goto, Akihiko Murakami, Masatsugu Ueda, Kanji Higashio, Yasushi Yamashita
Estimating the term…
The present invention relates to TCF mutant having a novel amino acid sequence which is obtained by mutagenesis of one or more amino acid between N-terminus and the first kringle of the amino acid sequence of native TCF and has lowered affinity to heparin and/or elevated biological activity. The present TCF mutant is prepared by gene manipulation of TCF. The TCF mutants of the present invention have proliferative activity and/or growth stimulative activity in hepatocyte and beneficial as a therapeutic agent for various hepatic diseases and an antitumor agent.
A TCF mutant which is obtained by mutagenesis of more than one amino acid residue at the position from N-terminus to the first kringle of the amino acid sequence of native TCF and has lowered affinity to heparin and/or elevated biological activity.
Dependencies are inferred from the claim text.